Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
MaxCyte ( (MXCT) ) just unveiled an update.
MaxCyte, Inc. announced a change in its major holdings, with BlackRock, Inc. acquiring additional voting rights, now holding 7.63% of the total voting rights in the company. This acquisition indicates a strengthened position for BlackRock in MaxCyte, potentially impacting the company’s influence in the biotechnology sector and signaling confidence in MaxCyte’s strategic direction and growth prospects.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell-based therapies and drug discovery. The company specializes in cell engineering technology, which is used for cell therapy development and drug discovery applications, targeting a range of markets including pharmaceuticals and biotech firms.
YTD Price Performance: 20.06%
Average Trading Volume: 56,507
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £401.2M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.
